)
Cipla will soon launch an innovative inhaler, called Synchrobreathe, which will bring important benefits for physicians, patients and healthcare providers on managing Obstructive Airway Disease (OAD). Synchrobreathe is a novel, breath-actuated inhaler (BAI) with a dose counter.
Frank Pieters, global head of respiratory for Cipla, said, “Simple and intuitive, Synchrobreathe is an innovation in managing respiratory disease. Synchrobreathe is attractive for patients as the inhaler is easy to use effectively. Equally importantly, Synchrobreathe will help cut the time healthcare providers need to spend to train patients in correct inhaler use. With this simple inhaler, the healthcare professional knows the patient will be able to use it easily and get the full benefit from every dose.”
Cipla made a presentation on Synchrobreathe at the South Africa Thoracic Society (SATS) conference in Cape Town (7-10 August 2015) where around 200 healthcare providers, pulmonologists, thoracic surgeons and other specialists present.
Paul Miller, CEO Cipla Medpro, South Africa added, “South Africa has amongst the highest asthma mortality rates in the world. As a leading company in the area of respiratory health in South Africa, we are proud to announce the development of this innovation for the first time to the medical community at the SATS congress. Synchrobreathe will definitely make patients’ lives easier in managing their Obstructive Airway Disease. Synchrobreathe is expected to reach the market in the current year.”
